GSK to work on potential Covid-19 shot with Canada's Medicago
Coronavirus chronicle
07 July, 2020, 06:45 pm
Last modified: 07 July, 2020, 06:44 pm
GSK, the world's largest vaccine maker, said the companies aim to make their vaccine available in the first half of next year and produce about 100 million doses by the end of 2021
FILE PHOTO: The GlaxoSmithKline (GSK) logo on top of GSK Asia House is seen through vertical louvres in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera
Britain's GSK said on Tuesday it will develop and test a potential Covid-19 vaccine using its booster technology and Canadian biopharmaceutical firm Medicago's coronavirus-like particles.
GSK, the world's largest vaccine maker, said the companies aim to make their vaccine available in the first half of next year and produce about 100 million doses by the end of 2021.
Early stage testing in humans is expected to begin in mid-July.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.